Australian Journal of General Practice
MBBS, FRACP, PhD, Head, Department of Endocrinology, Royal Darwin Hospital, NT; Head, Diabetes across the Lifecourse: Northern Australia Partnership, Menzies School of Health Research, Charles Darwin University, NT
Numerous glucose-lowering medications have been developed in recent years with growing evidence relating to their efficacy and safety.
Sodium–glucose co-transporter-2 inhibitors are becoming a cornerstone of therapy for type 2 diabetes, kidney disease and heart failure.